Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers

Quion, 1994, Clinical pharmacokinetics of pravastatin, Clin Pharmacokinet, 27, 94, 10.2165/00003088-199427020-00002 Hatanaka, 2000, Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events, Clin Pharmacokinet, 39, 397, 10.2165/00003088-200039060-00002 Haruyama, 1986, Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine, Chem Pharm Bull (Tokyo), 34, 1459, 10.1248/cpb.34.1459 Prisant, 2004, Preventing type II diabetes mellitus, J Clin Pharmacol., 44, 406, 10.1177/0091270004263018 Halstenson, 1992, Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment, J Clin Pharmacol., 32, 124, 10.1002/j.1552-4604.1992.tb03816.x Jandeleit-Dahm, 1999, Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy, Kidney Int Suppl., 71, S31, 10.1046/j.1523-1755.1999.07109.x Singhvi, 1990, Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects, Br J Clin Pharmacol., 29, 239, 10.1111/j.1365-2125.1990.tb03626.x Nishizato, 2003, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics, Clin Pharmacol Ther., 73, 554, 10.1016/S0009-9236(03)00060-2 Castaneda-Hernandez, 1993, Pharmacokinetics of oral nifedipine in different populations, J Clin Pharmacol., 33, 140, 10.1002/j.1552-4604.1993.tb03934.x Aldrete-Velasco, 1992, Efficacy of pravastatin as a hypolipidemic agent in patients with polygenic hypercholesterolemia, Arch Med Res., 23, 117 Lisker, 1990, Gene frequencies and admixture estimates in four Mexican urban centers, Hum Biol., 62, 791 Lisker, 1996, Genetic structure of autochthonous populations of Meso-America: Mexico, Hum Biol., 68, 395 Lisker, 1986, Gene frequencies and admixture estimates in a Mexico City population, Am J Phys Anthropol., 71, 203, 10.1002/ajpa.1330710207 K., 1998, Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection, J Chromatogr B Biomed Sci Appl., 708, 235, 10.1016/S0378-4347(97)00625-7 Causon, 1997, Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion, J Chromatogr B Biomed Sci Appl., 689, 175, 10.1016/S0378-4347(96)00297-6 Akaike, 1974, A new look at the statistical model identification, IEEE Trans Automat Contr., AC-19, 716, 10.1109/TAC.1974.1100705 Pan, 1990, Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia, Clin Pharmacol Ther., 48, 201, 10.1038/clpt.1990.136 Ogawa, 2003, Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects, J Clin Pharmacol., 43, 1268, 10.1177/0091270003257232 Fukazawa, 2004, Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese, Br J Clin Pharmacol., 57, 448, 10.1046/j.1365-2125.2003.02030.x Sugimoto, 2001, Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin, Clin Pharmacol Ther., 70, 518, 10.1067/mcp.2001.120025 Mazzu, 2000, Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin, Clin Pharmacol Ther., 68, 391, 10.1067/mcp.2000.110537